Table 4 Infectious complications
Type of infection | Supplemented group (n = 21) Number of patients per number of episodes (mean episodes ± SD per patient) | Placebo group (n = 20) Number of patients per number of episodes (mean episodes ± SD per patient) | P valuea |
|---|---|---|---|
Any infection | 21/43 (2.0 ± 1.0) | 20/69 (3.5 ± 1.2) | <0.001 |
Pneumonia | |||
Any | 11/13 (0.6 ± 0.7) | 20/35 (1.7 ± 1.1) | 0.001 |
Early (0 to 48 hours) | 6/6 (0.3 ± 0.5) | 4/4 (0.2 ± 0.5) | ns to 0.220 |
Nosocomial (>48 hours) | 7/7 (0.33 ± 0.5) | 16/31 (1.55 ± 1.0) | <0.001 |
VAPb | 6/6 (0.33 ± 0.5) | 13/13 (0.65 ± 0.5) | 0.023 |
Recurrentc | 2/2 (0.1 ± 0.3) | 13/19 (0.95 ± 0.8) | <0.001 |
Skin and soft tissue infection | 14/20 (0.95 ± 0.9) | 14/19 (0.95 ± 0.8) | ns to 0.871 |
Urinary tract infection | 3/4 (0.2 ± 0.5) | 4/5 (0.253 ± 0.6) | ns to 0.726 |
Bloodstream infection | 6/6 (0.3 ± 0.5) | 5/7 (0.35 ± 0.7) | ns to 0.734 |
Other infectiond | 0 | 4/4 (0.2 ± 0.4) | ns to 0.031 |